Business
CDX Antibody is Effective against ALL in vitro
CDX Antibody is Effective against ALL in vitro.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 5347A Hemogenyx Pharmaceuticals PLC 30 May 2019 \n\n \n \n \nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx\" or the \"Company\")\n \nCDX Antibody is Effective against ALL in vitro\n \n \nHemogenyx Pharmaceuticals plc (LSE: HEMO) announces the first data results from in vitro testing of its CDX bi-specific antibody (\"CDX antibody\") product candidate for the treatment of Acute Lymphoblastic Leukemia (\"ALL\"), a form of blood cancer.\n \nThe first data results demonstrate that the CDX antibody is capable of eliminating a subset of ALL cells in vitro. The CDX antibody was shown to target ALL cells that contain mixed-lineage leukemia 1 (MLL1) gene rearrangements and overexpress the protein FLT3. CDX binds to the FLT3 protein that is located on the surface of unwanted (target) cells, binds to the CD3 protein on the surface of T-cells, and ultimately redirects T-cells to kill the target cells. The Company is planning to verify the efficacy of CDX against ALL in vivo in the near future, using its proprietary advanced hematopoietic chimeric (\"AHC\") mice and similar testing to that which the Company used to demonstrate the efficacy of CDX against AML.\n \nBackground on Acute Lymphoblastic Leukemia\nALL is an aggressive form of blood cancer that affects both children and adults. While the prognosis for pediatric patients is generally good (80-90% survival), the prognosis for patients over 60 years of age remains very poor, with survival rates of only 10-15%. It is estimated that the value of the global therapeutic market for ALL was about $1.5B in 2016 with about $500M in the US alone.\n \nVladislav Sandler, Chief Executive Officer, commented, \"We are encouraged by this new data which demonstrates our continuing progress in the development and potential uses of our CDX antibody and the widening range of conditions to which it may be applicable. We previously demonstrated that CDX antibody may be effective in treating acute myeloid leukemia (\"AML\"), another type of aggressive blood cancer. This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor.\" \n \nMarket Abuse Regulation (MAR) Disclosure\nCertain information contained in this ...